Poxel : Corporate Presentation

Corporate Presentation

January 2022

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

2

Poxel's Investment Highlights

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC INFLAMMATION

DISORDERS

(cellular energy

homeostasisTISSUE

imbalances) DEGENERATION & CELL DEATH

apoptosis,

necrosis

3

• TWYMEEG® (Imeglimin) Approved And Launched for Type 2 Diabetes in Japan
• Strategic Focus on Rare Metabolic Indications and NASH
• Clinical Stage Pipeline with Global Operations
• Highly Experienced Management Team in Metabolic Diseases

Leadership Team

Highly Experienced Management Team; Extensive R&D and Metabolic Expertise

Based in France

Thomas Kuhn (Pharm D, MBA)

Chief Executive Officer and Co-founder

Sébastien Bolze (Pharm D, PhD)

EVP, Chief Operating Officer (COO), Co-founder

Pascale Fouqueray (MD, PhD)

EVP, Clinical Development &

Regulatory Affairs,

Co-founder

Sophie Bozec (PhD)

SVP, R&D Pharmacology &

Scientific Communication,

Co-founder

Anne Renevot

EVP, Chief Financial Officer

Quentin Durand

EVP, Chief Legal Officer

& Head of CSR

Sylvie Bertrand

Vice President, Human Resources

Based in the US

Noah Beerman (MBA)

EVP, Business Development & President, US Operations

David Moller (MD)

EVP, Chief Scientific Officer

(CSO)

Elizabeth Woo

SVP, Investor Relations, Public Relations & Corporate

Communications

Based in Japan

Takashi Kanedo (MD, PhD)

SVP, Medical and President of Poxel Japan KK

4

Robust Mid-to-Late Stage Metabolic Pipeline

Focus on Rare Metabolic Diseases and NASH

	Indication	MOA	Discovery	PH 1	PH 2 PH 3	Approved/	Partner/ Rights	Upcoming Milestones
	/PC	Marketed
Type 2 Diabetes (T2D)
TWYMEEG®				MRC							• TWYMEEG approved for T2D in Japan on
		T2D							June 23, 2021
Japan / Asia1			Modulator
									• Product launch September 16, 2021
Imeglimin			T2D with	MRC							• Exploring options to move the program forward
US / EU /			CKD stages
		Modulator							into Phase 3
Other			3b/4
NASH
PXL065			NASH	Non-Genomic						• Phase 2 results expected Q3 2022
		TZD2						•	505(b)(2) pathway
PXL770			NASH	AMPK3						• Successful Phase 2a Study
		Activator						• Evaluate next steps by year end 2022
Rare Metabolic Indications

PXL770	ALD4	AMPK
Activator
PXL065	ALD4	Non-Genomic
TZD
Next-Gen	Not	AMPK
AMPK	Disclosed	Activator
Next-Gen	Not	Non-Genomic
D-TZD	Disclosed	TZD

• Initiate Phase 2a Q1 2022
• Initiate Phase 2a Q1 2022
• Complete PC studies in 2021
• Select lead candidate(s)

1. Includes: China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos. 2. Deuterium-modified thiazolidinediione. 3. AMP-kinase. 4. X-linkedAdrenoLeukoDystrophy.

5